Boutique Biotech previously covered Affimed ($AFMD) in a long 10-page post spanning both company fundamentals and technical analysis. In their Q1 business update call last week, Affimed did not shed much light on AFM24 progress and disclosed that AFM26, which was partnered with Genentech, was discontinued. The call was not well received by investors, …
© 2024 Bohdan (Bo) Khomtchouk, Ph.D.
Substack is the home for great culture